Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

[1]  J. Au,et al.  Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Yang Yao,et al.  The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis. , 2013, Japanese journal of clinical oncology.

[3]  Jitesh Patel.  Drug combination extends late-stage pancreatic cancer survival in Phase III clinical trial. , 2013, Expert review of clinical pharmacology.

[4]  S. Fulda,et al.  Survivin as a prognostic/predictive marker and molecular target in cancer therapy. , 2012, Current medicinal chemistry.

[5]  N. Abbott,et al.  Incorporation of DOPE into Lipoplexes formed from a Ferrocenyl Lipid leads to Inverse Hexagonal Nanostructures that allow Redox-Based Control of Transfection in High Serum. , 2012, Soft matter.

[6]  J. Roth,et al.  Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans , 2012, PloS one.

[7]  J. Au,et al.  Relationships between Liposome Properties, Cell Membrane Binding, Intracellular Processing, and Intracellular Bioavailability , 2011, The AAPS Journal.

[8]  J. Au,et al.  Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. , 2011, Molecular pharmaceutics.

[9]  Y. Lei,et al.  Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance , 2010, Molecular and Cellular Biochemistry.

[10]  J. Au,et al.  Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.

[11]  S. Bartz,et al.  The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing , 2010, Nucleic acids research.

[12]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[13]  T. Park,et al.  siRNA delivery systems for cancer treatment. , 2009, Advanced drug delivery reviews.

[14]  Yu-cheng Tseng,et al.  Lipid-based systemic delivery of siRNA. , 2009, Advanced drug delivery reviews.

[15]  Ze Lu,et al.  Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.

[16]  S. Akhtar,et al.  Nonviral delivery of synthetic siRNAs in vivo. , 2007, The Journal of clinical investigation.

[17]  G. Torzilli,et al.  Survivin gene expression in chronic liver disease and hepatocellular carcinoma. , 2007, Hepato-gastroenterology.

[18]  W. Mann,et al.  Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. , 2007, Cancer research.

[19]  J. Au,et al.  Tumor Priming Enhances Delivery and Efficacy of Nanomedicines , 2007, Journal of Pharmacology and Experimental Therapeutics.

[20]  Ze Lu,et al.  Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel , 2007, Pharmaceutical Research.

[21]  Z. Dai,et al.  Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. , 2006, World journal of gastroenterology.

[22]  A. Klippel,et al.  A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.

[23]  Mark E. Davis,et al.  Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging , 2006, Nucleic acids research.

[24]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[25]  S. Miyatake,et al.  Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. , 2005, Surgery.

[26]  B. Vincenzi,et al.  Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients , 2005, British Journal of Cancer.

[27]  P. Sugarbaker,et al.  International Seminars in Surgical Oncology Prognostic Indicators in Peritoneal Carcinomatosis from Gastrointestinal Cancer , 2005 .

[28]  D. Levison,et al.  The assessment of cellular proliferation by immunohistochemistry: A review of currently available methods and their applications , 1992, The Histochemical Journal.

[29]  Li Jiang,et al.  Expression of survivin mRNA in peritoneal lavage fluid from patients with gastric carcinoma. , 2004, Chinese medical journal.

[30]  S. Miyatake,et al.  Survivin expression is a prognostic marker in pancreatic cancer patients. , 2004, Surgery.

[31]  K. Hirata,et al.  Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer , 2004, Journal of Translational Medicine.

[32]  Sérgio Simões,et al.  On the formulation of pH-sensitive liposomes with long circulation times. , 2004, Advanced drug delivery reviews.

[33]  Fengzhi Li,et al.  Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest* , 2004, Journal of Biological Chemistry.

[34]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[35]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Fengzhi Li.  Survivin study: What is the next wave? , 2003, Journal of cellular physiology.

[37]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[38]  Yasuo Watanabe,et al.  Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. , 2002, International journal of oncology.

[39]  M. Daidone,et al.  Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer , 2002, Cellular and Molecular Life Sciences CMLS.

[40]  T. Yoshikawa,et al.  An anti-apoptosis gene, survivin and telomerase expression in gastric cancer. , 2002, Hepato-gastroenterology.

[41]  D. Altieri,et al.  A p34(cdc2) survival checkpoint in cancer. , 2002, Cancer cell.

[42]  A. Markham,et al.  Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma , 2002, British Journal of Cancer.

[43]  M. Wientjes,et al.  Clinical aspects of drug delivery to tumors. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[44]  M. Carafa,et al.  Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. , 2002, International journal of pharmaceutics.

[45]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[46]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. Gadducci,et al.  Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. , 2000, Gynecologic oncology.

[49]  M. Wientjes,et al.  Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.

[50]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[51]  C. D. del Castillo,et al.  Peritoneal metastases in pancreatic carcinoma. , 1993, Hepato-gastroenterology.

[52]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[53]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .